A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era
Open Access
- 26 June 2020
- Vol. 56 (6), 315
- https://doi.org/10.3390/medicina56060315
Abstract
Background and objective: Despite medical advances, we are facing the unprecedented disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts have been made to seek proper treatments and response strategies, and the number of clinical trials has been rapidly increasing. In this time of the pandemic, it is believed that learning lessons from it would be meaningful in preparing for future pandemics. Thus, this study aims at providing a comprehensive landscape of COVID-19 related clinical trials based on the ClinicalTrials.gov database. Materials and methods: Up to 30 March 2020, we identified a total of 147 eligible clinical trials and reviewed the overview of the studies. Results: Until then, the most clinical trials were set up in China. Treatment approaches are the most frequent purpose of the registered studies. Chloroquine, interferon, and antiviral agents such as remdesivir, lopinavir, and ritonavir are agents under investigation in these trials. Conclusions: In this study, we introduced the promising therapeutic options that many researchers and clinicians are interested in, and to address the hidden issues behind clinical trials in this COVID-19 pandemic.Keywords
This publication has 39 references indexed in Scilit:
- Equipoise in Clinical TrialsCirculation Research, 2016
- Equipoise is necessary for randomising patients to clinical trialsActa Paediatrica, 2016
- Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV InfectionThe Journal of Infectious Diseases, 2015
- Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasomeNature Immunology, 2013
- The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort studyJournal of Infection, 2005
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirology Journal, 2005
- Clinical Trial Registration: A Statement from the International Committee of Medical Journal EditorsThe New England Journal of Medicine, 2004
- High–Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.2003
- For and against: Clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial FOR AGAINSTBMJ, 2000